Synmosa Biopharma Asset Resilience Ratio
Synmosa Biopharma asset resilience ratio. Synmosa Biopharma (4114) has an Asset Resilience Ratio of 7.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 4114 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Synmosa Biopharma (2016–2025)
Asset resilience ratio of Synmosa Biopharma from 2016 to 2025. This chart shows how Synmosa Biopharma's Asset Resilience Ratio has changed over time. Read Synmosa Biopharma balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Synmosa Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Synmosa Biopharma asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.04 Billion | 7.44% |
| Total Liquid Assets | NT$1.04 Billion | 7.44% |
Asset Resilience Insights
- Limited Liquidity: Synmosa Biopharma maintains only 7.44% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Synmosa Biopharma Industry Peers by Asset Resilience Ratio
Compare Synmosa Biopharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Synmosa Biopharma Asset Resilience Ratio by Year (2016–2025)
Synmosa Biopharma asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Synmosa Biopharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.44% | NT$1.04 Billion ≈ $32.77 Million |
NT$13.99 Billion ≈ $440.61 Million |
+1.75pp |
| 2024-12-31 | 5.68% | NT$699.34 Million ≈ $22.03 Million |
NT$12.30 Billion ≈ $387.65 Million |
-0.59pp |
| 2023-12-31 | 6.28% | NT$736.33 Million ≈ $23.20 Million |
NT$11.73 Billion ≈ $369.51 Million |
+3.32pp |
| 2022-12-31 | 2.96% | NT$331.68 Million ≈ $10.45 Million |
NT$11.20 Billion ≈ $352.94 Million |
+1.75pp |
| 2021-12-31 | 1.21% | NT$124.96 Million ≈ $3.94 Million |
NT$10.32 Billion ≈ $325.04 Million |
+0.18pp |
| 2020-12-31 | 1.03% | NT$107.01 Million ≈ $3.37 Million |
NT$10.38 Billion ≈ $326.95 Million |
-0.17pp |
| 2019-12-31 | 1.20% | NT$105.00 Million ≈ $3.31 Million |
NT$8.73 Billion ≈ $275.04 Million |
+1.14pp |
| 2018-12-31 | 0.07% | NT$5.05 Million ≈ $159.10K |
NT$7.54 Billion ≈ $237.70 Million |
-0.37pp |
| 2017-12-31 | 0.44% | NT$32.86 Million ≈ $1.04 Million |
NT$7.50 Billion ≈ $236.41 Million |
-0.01pp |
| 2016-12-31 | 0.45% | NT$30.52 Million ≈ $961.64K |
NT$6.79 Billion ≈ $213.90 Million |
-- |
About Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, gr… Read more